ArticleLeukemia & lymphoma2020

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Tanya Siddiqi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.